On August 20, Thermo Fisher Scientific rose 3.1% in regular trading, trading at $632.24/share, with turnover of $454 million. The advance came amid signals of strengthening ties with China, its second-largest global market.

On August 19, Shanghai Mayor Gong Zheng met with Thermo Fisher Chairman and CEO Marc Casper, expressing hope that the company would deepen investment in Shanghai, integrate into the city's biomedical industry ecosystem, and support local biopharma companies in expanding internationally. Casper affirmed plans to increase R&D investment in Shanghai and accelerate global business expansion. Days earlier on August 17, China's Vice Minister of Commerce also met with Thermo Fisher's global president to discuss bilateral trade relations and the company's China development.

The positive diplomatic backdrop adds to broader momentum including strong Q2 results reported July 23, where revenue of $11.99 billion beat estimates by 2.4% and adjusted EPS of $6.03 topped consensus by 5.6%. The company also recently completed the $1.08 billion divestiture of its microbiology business, sharpening its strategic focus on higher-growth segments.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)